Wei D He

US Patent:

6482834, Nov 19, 2002

Filed:

Apr 6, 2001

Appl. No.:

09/828633

Inventors:

Alfred P. Spada - Lansdale PA
Wei He - Collegeville PA
Michael R. Myers - Reading PA

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

A61K 3147

US Classification:

514311, 514312, 514313, 514314, 546153, 546159, 546171, 546178, 546179

Abstract:

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

US Patent:

6528526, Mar 4, 2003

Filed:

Sep 29, 2000

Appl. No.:

09/675746

Inventors:

Michael R. Myers - Reading PA
Wei He - Collegeville PA
Alfred P. Spada - Lansdale PA
Martin P. Maguire - Woburn MA

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

A61K 3133

US Classification:

514311, 514313, 514314, 514183

Abstract:

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

US Patent:

6696434, Feb 24, 2004

Filed:

Dec 12, 2002

Appl. No.:

10/317464

Inventors:

Michael R. Myers - Reading PA
Wei He - Collegeville PA
Alfred P. Spada - Lansdale PA
Martin P. Maguire - Woburn MA

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

A61K 3133

US Classification:

514183, 514311, 514312, 514313, 514314, 546153, 546171, 546178, 546179

Abstract:

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

US Patent:

6821962, Nov 23, 2004

Filed:

Feb 6, 2003

Appl. No.:

10/359983

Inventors:

Michael R. Myers - Reading PA
Wei He - Collegeville PA
Alfred P. Spada - Lansdale PA
Martin P. Maguire - Woburn MA

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

A61K 3133

US Classification:

514183, 514311, 514312, 514313, 514314, 546 26, 546112, 546134, 546135, 546137, 546152, 546167

Abstract:

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

US Patent:

6852712, Feb 8, 2005

Filed:

Feb 4, 2003

Appl. No.:

10/357882

Inventors:

Michael R. Myers - Reading PA, US
Wei He - Collegeville PA, US
Alfred P. Spada - Lansdale PA, US
Martin P. Maguire - Woburn MA, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

A61K031/33
A61K031/498
C07D241/36

US Classification:

514183, 514248, 514249, 5142521, 51425506, 544336, 544338, 544353, 544354, 544356, 544349

Abstract:

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

US Patent:

7041681, May 9, 2006

Filed:

Mar 26, 2003

Appl. No.:

10/400006

Inventors:

Henry J. Breslin - Lansdale PA, US
Wei He - Audubon PA, US
Robert W. Kavash - Glenside PA, US

Assignee:

Janssen Pharmaceutica N.V. - Beerse

International Classification:

A61K 31/454
A61K 31/4725
C07D 401/04
C07D 401/14

US Classification:

514326, 546210, 546187, 546146, 544 60, 544128, 544129, 544360, 544363, 514316, 514307, 514252, 5142355, 5142278

Abstract:

This invention is directed towards novel compounds as opioid receptor modulators, antagonists, and agonists useful for the treatment of opioid modulated disorders such as pain and gastrointestinal disorders.

US Patent:

7202381, Apr 10, 2007

Filed:

Mar 14, 2005

Appl. No.:

11/079573

Inventors:

Henry J. Breslin - Lansdale PA, US
Wei He - Audubon PA, US
Robert W. Kavash - Glenside PA, US

Assignee:

Janssen Pharmaceutica, NV

International Classification:

C07C 53/134
C07D 213/24

US Classification:

562496, 546314, 562443, 562448, 560 38, 564182

Abstract:

This invention is directed towards novel compounds as opioid receptor modulators, antagonists, and agonists useful for the treatment of opioid modulated disorders such as pain and gastrointestinal disorders.

US Patent:

7629488, Dec 8, 2009

Filed:

Mar 6, 2006

Appl. No.:

11/368564

Inventors:

Chaozhong Cai - North Wales PA, US
Wei He - Audubon PA, US

Assignee:

Janssen Pharmaceutica N.V. - Beerse

International Classification:

C07C 51/10

US Classification:

562406, 562400, 562405

Abstract:

The present invention is directed to novel processes for the preparation of opioid modulators (agonists and antagonists) and intermediates in their synthesis. The opioid modulators are useful for the treatment and prevention of as pain and gastrointestinal disorders.